Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics (Nasdaq: VERA) announced inducement awards granted to Jason S. Carter, their new Chief Legal Officer, on November 18, 2024. The awards include a non-qualified stock option to purchase 108,000 shares of Class A common stock at $44.81 per share and restricted stock units (RSUs) for 53,000 shares. The stock options will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest 25% annually over four years starting November 20, 2024, subject to continued employment.
Vera Therapeutics (Nasdaq: VERA) ha annunciato premi di incentivo concessi a Jason S. Carter, il loro nuovo Chief Legal Officer, il 18 novembre 2024. I premi includono un'opzione su azioni non qualificata per acquistare 108.000 azioni di azioni comuni di Classe A a $44.81 per azione e unità azionarie vincolate (RSUs) per 53.000 azioni. Le opzioni sulle azioni matureranno nell'arco di quattro anni, con il 25% che matura dopo un anno e il restante mensilmente negli successivi 36 mesi. Le RSUs matureranno il 25% annualmente per quattro anni a partire dal 20 novembre 2024, a condizione di continuare l'impiego.
Vera Therapeutics (Nasdaq: VERA) anunció premios de incentivo otorgados a Jason S. Carter, su nuevo Director Legal, el 18 de noviembre de 2024. Los premios incluyen una opción de compra de acciones no calificadas para adquirir 108,000 acciones de acciones comunes Clase A a $44.81 por acción y unidades de acciones restringidas (RSUs) para 53,000 acciones. Las opciones sobre acciones se consolidarán durante cuatro años, con un 25% consolidándose después de un año y el resto mensualmente durante 36 meses. Las RSUs se consolidarán al 25% anualmente durante cuatro años a partir del 20 de noviembre de 2024, sujeto a empleo continuo.
베라 테라퓨틱스(Vera Therapeutics) (Nasdaq: VERA)는 2024년 11월 18일에 새로운 법무 담당자 제이슨 S. 카터에게 주어지는 유인 보상을 발표했습니다. 보상에는 108,000주의 A 클래스 보통주를 주당 $44.81에 구매할 수 있는 비자격 주식 옵션과 53,000주에 대한 제한 주식 단위(RSUs)가 포함됩니다. 주식 옵션은 4년에 걸쳐 발생하며, 1년 후 25%가 발생하고 나머지는 36개월 동안 매달 발생합니다. RSUs는 2024년 11월 20일부터 시작하여 4년 동안 매년 25%씩 발생합니다. 이는 계속해서 고용 상태를 유지해야 합니다.
Vera Therapeutics (Nasdaq: VERA) a annoncé des primes d'incitation attribuées à Jason S. Carter, leur nouveau directeur juridique, le 18 novembre 2024. Les primes comprennent une option d'achat d'actions non qualifiée pour acquérir 108 000 actions de l'action ordinaire de Classe A au prix de 44,81 $ par action et des unités d'actions restreintes (RSUs) pour 53 000 actions. Les options sur actions prendront effet sur une période de quatre ans, avec 25 % prenant effet après un an et le reste mensuellement sur 36 mois. Les RSUs prendront effet à raison de 25 % par an sur quatre ans à partir du 20 novembre 2024, sous réserve de maintien de l'emploi.
Vera Therapeutics (Nasdaq: VERA) gab am 18. November 2024 bekannt, dass Jason S. Carter, deren neuer Chief Legal Officer, Anreizvergütungen zugesprochen wurden. Zu den Vergütungen gehören eine nicht qualifizierte Aktienoption zum Kauf von 108.000 Aktien der Klasse A zum Preis von 44,81 $ pro Aktie sowie Restricted Stock Units (RSUs) für 53.000 Aktien. Die Aktienoptionen werden über vier Jahre vesten, wobei 25 % nach einem Jahr und der Rest monatlich über 36 Monate vesten. Die RSUs vesten 25 % jährlich über einen Zeitraum von vier Jahren, beginnend am 20. November 2024, vorausgesetzt, der Mitarbeiter bleibt beschäftigt.
- Stock price showing strength with options granted at $44.81 per share
- Company strengthening executive team with new Chief Legal Officer appointment
- Potential shareholder dilution from 161,000 new shares (108,000 options + 53,000 RSUs)
BRISBANE, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on November 18, 2024, the Compensation Committee of Vera’s Board of Directors granted inducement awards consisting of a non-qualified stock option to purchase 108,000 shares of Class A common stock and restricted stock units (RSUs) for 53,000 shares of Class A common stock to Jason S. Carter, Vera’s new Chief Legal Officer, under Vera’s 2024 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employee’s employment in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock option granted on November 18, 2024 has an exercise price per share equal to
About Vera
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. For more information, please visit www.veratx.com.
For more information, please contact:
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
Media Contact:
Madelin Hawtin
LifeSci Communications
MHawtin@lifescicomms.com
FAQ
What inducement grants did Vera Therapeutics (VERA) announce on November 22, 2024?
What is the vesting schedule for VERA's November 2024 inducement grants?
What was the exercise price of VERA's stock options granted on November 18, 2024?
